Craig Tooman

Craig Allen Tooman was the founder of Stockbourne LLC, founded in 2011, where the title held was Principal from 2011 to 2012.
Current jobs include Director at Silence Therapeutics, Inc. since 2021; Director at Verte Therapeutics LLC; Independent Non-Executive Director at Coiled Therapeutics Plc starting in 2026; Member-Supervisory Board at CureVac SE since 2019; and Independent Member-Supervisory Board at CureVac NV since 2019.
Former jobs include President, Chief Executive Officer & Director at Aratana Therapeutics, Inc. in 2019; Chief Executive Officer at Avanzar Medical, Inc. from 2012 to 2014; President, CEO & Executive Director at Silence Therapeutics Plc from 2022 to 2025; Independent Director at InSite Vision, Inc. from 2011 to 2015; Director at Xanodyne Pharmaceuticals, Inc.; Director at Aratana Therapeutics NV; Chief Operating & Financial Officer, Director at Vyome Therapeutics, Inc. from 2019 to 2021; Director at Vet Therapeutics, Inc.; Director at ViroVet NV; Independent Non-Executive Director at Ondine Biomedical, Inc. from 2021 to 2024; Chief Financial Officer, Executive VP & Head-IR at Enzon Pharmaceuticals, Inc. in 2010; Vice President-Investor Relations at Pharmacia & Upjohn, Inc.; SVP-Strategic Planning & Corporate Communications at ILEX Oncology, Inc. in 2005; Chief Financial Officer & Senior Vice President at Ikaria, Inc. from 2010 to 2011; Vice President-Investor Relations at Pharmacia Corp.
Education includes an MBA from The University of Chicago and undergraduate studies at Kalamazoo College.